Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper.

Girolomoni G, Griffiths CE, Krueger J, Nestle FO, Nicolas JF, Prinz JC, Puig L, Ståhle M, van de Kerkhof PC, Allez M, Emery P, Paul C.

J Dermatolog Treat. 2015 Apr;26(2):103-12. doi: 10.3109/09546634.2014.880396. Epub 2014 Feb 19. Review.

PMID:
24547907
2.

Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2009;9(27):1-66. Epub 2009 Nov 1.

3.

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution.

Kuek A, Hazleman BL, Ostör AJ.

Postgrad Med J. 2007 Apr;83(978):251-60. Review.

4.

Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.

Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

PMID:
22843208
5.

Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients.

Antonio JR, Sanmiguel J, Cagnon GV, Augusto MS, Godoy MF, Pozetti EM.

An Bras Dermatol. 2016 May-Jun;91(3):306-10. doi: 10.1590/abd1806-4841.20164292.

6.

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.

Nirula A, Nilsen J, Klekotka P, Kricorian G, Erondu N, Towne JE, Russell CB, Martin DA, Budelsky AL.

Rheumatology (Oxford). 2016 Dec;55(suppl 2):ii43-ii55. Review.

PMID:
27856660
7.
8.

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G.

Am J Clin Dermatol. 2008;9(1):1-14. Review. Erratum in: Am J Clin Dermatol. 2008;9(5):347.

PMID:
18092839
9.

[Methotrexate treatment in non-cancerous disorders].

Cogan E.

Rev Med Brux. 1995 Jul-Aug;16(4):300-3. French.

PMID:
7481247
10.

Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment.

van den Reek JM, Pijls PA, Tummers M, van Riel PC, Kievit W, Hoentjen F, de Jong EM.

J Am Acad Dermatol. 2016 Jan;74(1):177-9. doi: 10.1016/j.jaad.2015.08.010. No abstract available.

PMID:
26702800
11.

Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review.

Depont F, Berenbaum F, Filippi J, Le Maitre M, Nataf H, Paul C, Peyrin-Biroulet L, Thibout E.

PLoS One. 2015 Dec 16;10(12):e0145076. doi: 10.1371/journal.pone.0145076. eCollection 2015. Review.

12.

Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.

Allen PB, Olivera P, Emery P, Moulin D, Jouzeau JY, Netter P, Danese S, Feagan B, Sandborn WJ, Peyrin-Biroulet L.

Aliment Pharmacol Ther. 2017 Apr;45(8):1058-1072. doi: 10.1111/apt.13995. Epub 2017 Mar 1. Review.

PMID:
28247573
13.

Urine metabolome profiling of immune-mediated inflammatory diseases.

Alonso A, Julià A, Vinaixa M, Domènech E, Fernández-Nebro A, Cañete JD, Ferrándiz C, Tornero J, Gisbert JP, Nos P, Casbas AG, Puig L, González-Álvaro I, Pinto-Tasende JA, Blanco R, Rodríguez MA, Beltran A, Correig X, Marsal S; IMID Consortium.

BMC Med. 2016 Sep 8;14(1):133. doi: 10.1186/s12916-016-0681-8.

14.

The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities.

Piérard GE, Piérard-Franchimont C, Szepetiuk G, Paquet P, Quatresooz P.

Expert Opin Biol Ther. 2010 Aug;10(8):1197-208. doi: 10.1517/14712598.2010.500283. Review.

PMID:
20560729
15.

Technology evaluation: ISIS-104838, OraSense.

Kennewell P.

Curr Opin Mol Ther. 2003 Feb;5(1):76-80.

PMID:
12669475
16.

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.

Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP.

Ann Rheum Dis. 2013 Apr;72(4):517-24. doi: 10.1136/annrheumdis-2011-201244. Epub 2012 May 5. Review.

17.

Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases.

Fragoulis GE, Siebert S, McInnes IB.

Annu Rev Med. 2016;67:337-53. doi: 10.1146/annurev-med-051914-021944. Epub 2015 Nov 4. Review.

PMID:
26565676
18.

Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.

Schafer JA, Kjesbo NK, Gleason PP.

J Manag Care Pharm. 2010 Jul-Aug;16(6):402-16. Review.

19.

[A case of psoriasis induced by infliximab treatment for Crohn's disease].

Jwa YJ, Kim NH, Park HJ, Park JS, Bae WK, Kim KA, Lee JS, Moon YS.

Korean J Gastroenterol. 2010 Nov;56(5):324-8. Korean.

20.

New-onset psoriasis associated with adalimumab: a report of two cases.

Glenn CJ, Kobraei KB, Russo JJ.

Dermatol Online J. 2011 Sep 15;17(9):15.

Supplemental Content

Support Center